Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

GFI Sees Growth In Australian Medical Cannabis Prescriptions

Greenfern Industries' GMP medicine prescription sales in the Australian market are going from strength to strength.

The company began distribution of its GFI Pharma-branded medicinal cannabis oil tinctures with Australian partner Cannvalate in November 2021. Since then, GFI has seen an average new patient increase of 42% month on month with an average return patient rate of 27% month on month.

This year-to-date GFI has more than 500 patients prescribed to their medicines. Of those, 144 have returned one or more times.

Managing director Dan Casey said the company had seen a significant uplift in the month of May with GFI Pharma CBD100 medicine becoming available with 158 new patients in the month of May alone.

"This adds to our already available Balanced Plus 12.5:12.5CBD/THC and our THC25 medicines. With new products currently in manufacturing we're looking to see the growing patient base into the second quarter of this year.

"We will look to bring these products, which are full spectrum (meaning they have trace elements of other cannabinoids in the formulation), to the New Zealand market pending MedSafe approval in the future."

Australia's legal cannabis market is expected to reach USD$375.7 million by 2028 and is expected to expand at a compound annual growth rate of 32.7% from 2021 to 2028.

Clinical trials update

Therapeutic Goods Administration (TGA) statistics recently released show that patients being prescribed medicinal cannabis are getting younger with 18–44-year-olds making up 59% of the market.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Interestingly prescriptions for anxiety have trebled in its market share from 10% in early 2020 to 31% in 2022.

"This is perhaps a sign of the current times, but it also reinforces our clinic trials pathway for over-the-counter CBD perusing an anxiety indication," Dan said.

"Our clinical trial protocols are currently in the writing phase and a successful outcome will lead to a share of what is destined to be an AUD$250 million market at maturity. With the deidentified patient data sets that we acquire as part of the prescriber process, we are gathering valuable indication data that will position us well for directions of future clinical trial pathways."

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.